Low-Grade Esthesioneuroblastoma Presenting as SIADH: A Review of Atypical Manifestations

Senchak, Andrew J.; Freeman, Judy H.; Ruhl, Douglas S.; Senchak, Jordan; Klem, Christopher

doi:10.1155/2012/582180

Cited by 15 publications

(22 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other studies have reported secretion of adrenocorticotropic hormone from esthesioneuroblastomas . Syndrome of inappropriate antidiuretic hormone has also been reported in patients with esthesioneuroblastoma , …”

Section: Discussionmentioning

confidence: 89%

Intraoperative hypertensive crisis due to a catecholamine‐secreting esthesioneuroblastoma

et al. 2015

View full text Add to dashboard Cite

Background Although uncommon, esthesioneuroblastomas may produce clinically significant amounts of catecholamines. Methods We report a patient with a catecholamine-secreting esthesioneuroblastoma who developed intraoperative hypertensive crisis. Results A patient with history of hypertension was referred to our skull base center for management of a residual esthesioneuroblastoma. A staged endonasal endoscopic approach was planned. At the conclusion of the first stage, a hypertensive crisis occurred. Work-up revealed elevated levels of serum and urinary catecholamines. The patient was treated with alpha adrenoceptor blockade prior to the second stage. Serum catecholamine levels following this second stage were normal. On immunohistochemical analysis, the tumor cells were found to be positive for tyrosine hydroxylase, the rate limiting enzyme in cathecholamine synthesis, and achaete-scute homologue 1, a transcription factor essential in the development of olfactory and sympathetic neurons. Conclusion Catecholamine production should be considered in the differential of unexpected extreme hypertension during surgical resection of esthesioneuroblastoma.

show abstract

Section: Discussionmentioning

confidence: 89%

Intraoperative hypertensive crisis due to a catecholamine‐secreting esthesioneuroblastoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…9 There are several reported cases of paraneoplastic syndromes related to vasopressin-or catecholamine-secreting esthesioneuroblastomas. 30,31 The majority of cases exhibit indolent growth; hence, symptoms may have been present for a prolonged period. Therefore, it is not surprising that incidental diagnosis on radiological investigation is often the initial presentation, as was the case with two patients in this study.…”

Section: Discussionmentioning

confidence: 99%

Changing Trends in the Management of Esthesioneuroblastoma: Irish and International Perspectives

et al. 2017

View full text Add to dashboard Cite

Evaluation of the changing trends in esthesioneuroblastoma in an Irish context and review of management options nationally to clarify the best current therapeutic approach by comparing with international research on this uncommon malignancy. Retrospective review. Tertiary referral center. All patients presenting with esthesioneuroblastoma in Beaumont hospital or on the National Cancer Registry of Ireland between 1994 and 2013. Recurrence-free and overall survival. During the study period, 32 cases of esthesioneuroblastoma were diagnosed (0.4 per million per year). Average age at diagnosis was 57 years; however, two cases were under 20. The majority (62.5%) were male. Patients predominantly presented with epistaxis or nasal congestion (73%), while two cases were identified incidentally on radiological investigations. Twenty-seven cases underwent primary surgical management (two post neo-adjuvant treatment) with seventeen requiring bifrontal craniotomy. Twenty-four of these received postoperative radiation therapy. Overall, 5-year survival was 65%. Kadish A/B patients exhibited 100% 5-year disease-specific survival versus 54% in Kadish C/D ( = 0.011). Hyams grade I/II patients exhibited 75% 5-year disease-specific survival versus 63% in Hyams grade III/IV ( = 0.005). Patients treated endoscopically exhibited 100% 5-year disease-specific survival versus 51% in those treated via an open approach ( = 0.102). Many controversies exist in the diagnosis and management of this condition. Despite this, results from Irish data are mostly concordant with the international literature. The rising incidence of this disease may represent improved pathological recognition. An increasing number of esthesioneuroblastoma cases are being successfully treated via endoscopic surgery.

show abstract

“…Other studies have reported secretion of adrenocorticotropic hormone (ACTH) from esthesioneuroblastomas (17)(18)(19)(20)(21)(22)(23)(24) . Syndrome of inappropriate antidiuretic hormone (SIADH) has also been reported in patients with esthesioneuroblastoma (9,(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36) .…”

Section: Discussionmentioning

confidence: 99%

Intraoperative Hypertensive Crisis Due to a Catecholamine-Secreting Esthesioneuroblastoma

Salmasi¹,

Schiavi²,

Orr³

et al. 2012

J Neurol Surg B

View full text Add to dashboard Cite

show abstract

Low-Grade Esthesioneuroblastoma Presenting as SIADH: A Review of Atypical Manifestations

Cited by 15 publications

References 43 publications

Intraoperative hypertensive crisis due to a catecholamine‐secreting esthesioneuroblastoma

Intraoperative hypertensive crisis due to a catecholamine‐secreting esthesioneuroblastoma

Changing Trends in the Management of Esthesioneuroblastoma: Irish and International Perspectives

Intraoperative Hypertensive Crisis Due to a Catecholamine-Secreting Esthesioneuroblastoma

Contact Info

Product

Resources

About